Comprehensive engineering of the CasX-Editor to generate a therapeutically optimized genome editor

CRISPR-based genetic modification is enabling curative, one-time treatments, but extending its use to more diseases will require increasing potency at low doses while avoiding unintended genomic modification. CRISPR technologies derive from microbial nucleases, such as Cas9, whose properties evolved for antiviral defense rather than precision editing in human cells. Although these systems can be engineered for greater activity or specificity, improving both properties to meet the challenges of in vivo delivery in large animals remains challenging. Here we used iterative molecular engineering of the Cas12e protein and its guide RNA to produce the X-Editor (XE), a compact nuclease platform that combines robust in vivo activity with exceptional genomic specificity. Screening tens of thousands of protein variants and guide designs and iteratively testing and combining beneficial mutations yielded an enzyme with more than 100-fold higher editing activity in human cells. Cryo-electron microscopy revealed novel inter- and intramolecular interactions driving enhanced function. XE mRNA was delivered to nonhuman primate liver via lipid nanoparticle with guides for two distinct targets. At both targets, XE demonstrated greater editing at lower doses than comparable preclinical data from Cas9-based therapies that are now in clinical testing. No off-target editing was detected for either guide in full specificity assessments performed in primary human hepatocytes at doses tenfold above the on-target effective concentration (EC90). These findings establish that more potent in vivo editing and stringent genomic specificity can be jointly engineered into a naturally compact CRISPR system for delivery using adeno-associated virus (AAV) or lipid nanoparticle (LNP) delivery strategies. These results provide a new foundation for advanced genetic medicines that demand lower dosing and greatly reduced off-target risk.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.10.765514
Primary Topic
CRISPR and Genetic Engineering
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Comprehensive engineering of the CasX-Editor to generate a therapeutically optimized genome editor

Allison L. Didychuk, Benjamin L. Oakes, Santhosh Karanth, Christie C. Sze et al.
bioRxiv (Cold Spring Harbor Laboratory)
CRISPR and Genetic Engineering
preprint

Comprehensive engineering of the CasX-Editor to generate a therapeutically optimized genome editor

Allison L. Didychuk, Benjamin L. Oakes, Santhosh Karanth, Christie C. Sze, Farah H. Bardai, Addison V. Wright, Keith E. Szulwach, Ashley E. Graham, Michelle Eggers, Elizabeth Bailey, Cécile Fortuny, Shyam Sundhar Bale, Shiyi Wang, Myles Hochman, Sarah K. Denny, Kirsten A. Reimer, Jennifer Saraya, Ross White, TC Steven Keller, Matthew R Gardner, Sean A Higgins, Kristin Wucherer, Kristina Bender, Ben Demaree, Isabel Colin
preprint en

Abstract

CRISPR-based genetic modification is enabling curative, one-time treatments, but extending its use to more diseases will require increasing potency at low doses while avoiding unintended genomic modification. CRISPR technologies derive from microbial nucleases, such as Cas9, whose properties evolved for antiviral defense rather than precision editing in human cells. Although these systems can be engineered for greater activity or specificity, improving both properties to meet the challenges of in vivo delivery in large animals remains challenging. Here we used iterative molecular engineering of the Cas12e protein and its guide RNA to produce the X-Editor (XE), a compact nuclease platform that combines robust in vivo activity with exceptional genomic specificity. Screening tens of thousands of protein variants and guide designs and iteratively testing and combining beneficial mutations yielded an enzyme with more than 100-fold higher editing activity in human cells. Cryo-electron microscopy revealed novel inter- and intramolecular interactions driving enhanced function. XE mRNA was delivered to nonhuman primate liver via lipid nanoparticle with guides for two distinct targets. At both targets, XE demonstrated greater editing at lower doses than comparable preclinical data from Cas9-based therapies that are now in clinical testing. No off-target editing was detected for either guide in full specificity assessments performed in primary human hepatocytes at doses tenfold above the on-target effective concentration (EC90). These findings establish that more potent in vivo editing and stringent genomic specificity can be jointly engineered into a naturally compact CRISPR system for delivery using adeno-associated virus (AAV) or lipid nanoparticle (LNP) delivery strategies. These results provide a new foundation for advanced genetic medicines that demand lower dosing and greatly reduced off-target risk.

bioRxiv (Cold Spring Harbor Laboratory)
Yale University (US)
Good health and well-being
CRISPR and Genetic Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon